Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51

References

• Howe H L, Wu X, Ries L A, Cokkinides V, Ahmed F, Jemal A, et al. Annual report to the nation on the status of cancer, 1975 – 2003, featuring cancer among U.S. hispanic/latino populations. Cancer 2006; 107: 1711–1742
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Nelms K, Keegan A D, Zamorano J, Ryan J J, Paul W E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701–738
   PubMed Web of Science ®Google Scholar
• Jiang H, Harris M B, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000; 105(Pt 1)1063–1070
   PubMed Web of Science ®Google Scholar
• Kriegel M A, Tretter T, Blank N, Schiller M, Gabler C, Winkler S, et al. Interleukin-4 supports interleukin-12-induced proliferation and interferon-gamma secretion in human activated lymphoblasts and T helper type 1 cells. Immunology 2006; 119: 43–53
   PubMed Web of Science ®Google Scholar
• Leonard W J, Noguchi M, Russell S M. Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID). Adv Exp Med Biol 1994; 365: 225–232
   PubMedGoogle Scholar
• Obiri N I, Debinski W, Leonard W J, Puri R K. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995; 270: 8797–8804
   PubMed Web of Science ®Google Scholar
• Murata T, Taguchi J, Puri R K. Interleukin-13 receptor alpha′ but not alpha chain: a functional component of interleukin-4 receptors. Blood 1998; 91: 3884–3891
   PubMed Web of Science ®Google Scholar
• Obiri N I, Hillman G G, Haas G P, Sud S, Puri R K. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993; 91: 88–93
   PubMed Web of Science ®Google Scholar
• Topp M S, Papadimitriou C A, Eitelbach F, Oelmann E, Koehler B, Oberberg D, et al. Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism. Leuk Lymphoma 1995; 19: 319–328
   PubMed Web of Science ®Google Scholar
• Gooch J L, Lee A V, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 1998; 58: 4199–4205
   PubMed Web of Science ®Google Scholar
• Topp M S, Papadimitriou C A, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995; 55: 2173–2176
   PubMed Web of Science ®Google Scholar
• Lahm H, Schnyder B, Wyniger J, Borbenyi Z, Yilmaz A, Car B D, et al. Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int J Cancer 1994; 59: 440–447
   PubMed Web of Science ®Google Scholar
• Toi M, Bicknell R, Harris A L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992; 52: 275–279
   PubMed Web of Science ®Google Scholar
• Crawford R M, Finbloom D S, Ohara J, Paul W E, Meltzer M S. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol 1987; 139: 135–141
   PubMed Web of Science ®Google Scholar
• Mule J J, Smith C A, Rosenberg S A. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med 1987; 166: 792–797
   PubMed Web of Science ®Google Scholar
• Tepper R I, Pattengale P K, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Manabe A, Coustan-Smith E, Kumagai M, Behm F G, Raimondi S C, Pui C H, et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood 1994; 83: 1731–1737
   PubMed Web of Science ®Google Scholar
• Schnyder B, Lahm H, Woerly G, Odartchenko N, Ryffel B, Car B D. Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1. Biochem J 1996; 315(Pt 3)767–774
   PubMed Web of Science ®Google Scholar
• Jackson J G, White M F, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 1998; 273: 9994–10003
   PubMed Web of Science ®Google Scholar
• Gooch J L, Christy B, Yee D. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 2002; 4: 324–331
   PubMed Web of Science ®Google Scholar
• Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 2006; 66: 1491–1499
   PubMed Web of Science ®Google Scholar
• Schwarz M A, Tardelli L, Macosko H D, Sullivan L M, Narula S K, Fine J S. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 1995; 55: 3692–3696
   PubMed Web of Science ®Google Scholar
• Defrance T, Fluckiger A C, Rossi J F, Magaud J P, Sotto J J, Banchereau J. Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. Blood 1992; 79: 990–996
   PubMed Web of Science ®Google Scholar
• Taylor C W, Grogan T M, Salmon S E. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 1990; 75: 1114–1118
   PubMed Web of Science ®Google Scholar
• Taylor C W, LeBlanc M, Fisher R I, Moore D F, Sr, Roach R W, Elias L, et al. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. Anticancer Drugs 2000; 11: 695–700
   PubMed Web of Science ®Google Scholar
• Fabre-Guillevin E, Tabrizi R, Coulon V, Monnereau A, Eghbali H, Soubeyran I, et al. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006; 47: 603–611
   PubMed Web of Science ®Google Scholar
• Kaplan M H, Daniel C, Schindler U, Grusby M J. Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol Cell Biol 1998; 18: 1996–2003
   PubMed Web of Science ®Google Scholar
• Hu Z Q, Zhao W H, Shimamura T, Galli S J. Interleukin-4-triggered, STAT6-dependent production of a factor that induces mouse mast cell apoptosis. Eur J Immunol 2006; 36: 1275–1284
   PubMed Web of Science ®Google Scholar
• Pircher T J, Petersen H, Gustafsson J A, Haldosen L A. Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. Mol Endocrinol 1999; 13: 555–565
   PubMed Web of Science ®Google Scholar
• Al-Shami A, Naccache P H. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. J Biol Chem 1999; 274: 5333–5338
   PubMed Web of Science ®Google Scholar
• Gollob J A, Schnipper C P, Murphy E A, Ritz J, Frank D A. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 1999; 162: 4472–4481
   PubMed Web of Science ®Google Scholar
• David M, Ford D, Bertoglio J, Maizel A L, Pierre J. Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene 2001; 20: 6660–6668
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003; 101: 433–440
   PubMed Web of Science ®Google Scholar
• Lu X, Nechushtan H, Ding F, Rosado M F, Singal R, Alizadeh A A, et al. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood 2005; 105: 2924–2932
   PubMed Web of Science ®Google Scholar
• Lossos I S. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6351–6357
   PubMed Web of Science ®Google Scholar
• Nechushtan H, Rosenblatt J D, Lossos I S. IL-4 affects proliferation, chemosensitivity-and rituximab sensitivity of germinal center B-cell like (GCB) and activated B-cell like (ABC) diffuse large B-cell lymphoma differently. ASH Annu Meet Abstr 2004; 104: 242
   Google Scholar
• Sasaki Y, Mita H, Toyota M, Ishida S, Morimoto I, Yamashita T, et al. Identification of the interleukin 4 receptor alpha gene as a direct target for p73. Cancer Res 2003; 63: 8145–8152
   PubMed Web of Science ®Google Scholar
• Husain S R, Kreitman R J, Pastan I, Puri R K. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med 1999; 5: 817–822
   PubMed Web of Science ®Google Scholar
• Joshi B H, Leland P, Silber J, Kreitman R J, Pastan I, Berger M, et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br J Cancer 2002; 86: 285–291
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kawakami M, Puri R K. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 2001; 21: 299–310
   PubMed Web of Science ®Google Scholar
• Kay N E, Bone N D, Lee Y K, Jelinek D F, Leland P, Battle T E, et al. A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. Leuk Res 2005; 29: 1009–1018
   PubMed Web of Science ®Google Scholar